David M Schuster

List of Publications by Citations

Source: https://exaly.com/author-pdf/8654322/david-m-schuster-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149 papers	4,082 citations	34 h-index	60 g-index
160 ext. papers	4,816 ext. citations	3.8 avg, IF	5.4 L-index

#	Paper	IF	Citations
149	Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 1385-92	4	213
148	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 540-557	8.8	198
147	Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. *Journal of Nuclear Medicine*, **2007**, 48, 56-63	8.9	189
146	Hyperspectral imaging and quantitative analysis for prostate cancer detection. *Journal of Biomedical Optics*, **2012**, 17, 076005	3.5	149
145	Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. *Journal of*	2.5	141
144	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer. *Journal of Urology*, **2017**, 197, 676-683	2.5	130
143	Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. *Radiology*, **2011**, 259, 852-61	20.5	128
142	Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1773-83	8.8	115
141	Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. *Nature Methods*, **2015**, 12, 427-32	21.6	113
140	Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. *Journal of Nuclear Medicine*, **2014**, 55, 1986-92	8.9	112
139	F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. *Head and Neck*, **2005**, 27, 494-502	4.2	103
138	Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. *Nuclear Medicine and Biology*, **2012**, 39, 109-19	2.1	94
137	MR-based attenuation correction for hybrid PET-MR brain imaging systems using deformable image registration. *Medical Physics*, **2010**, 37, 2101-9	4.4	94
136	The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. *Journal of Urology*, **2019**, 201, 322-331	2.5	81
135	Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. *Journal of Nuclear Medicine*, **2007**, 48, 1017-20	8.9	79
134	Update on F-Fluciclovine PET for Prostate Cancer Imaging. *Journal of Nuclear Medicine*, **2018**, 59, 733-739	8.9	78
133	Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. *Medicinal Research Reviews*, **2012**, 32, 868-905	14.4	74

132	Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer. *Clinical Nuclear Medicine*, **2017**, 42, e22-e28	1.7	72
131	Differences in neural activation for object-directed grasping in chimpanzees and humans. *Journal of Neuroscience*, **2013**, 33, 14117-34	6.6	64
130	Radionuclide imaging for hyperparathyroidism (HPT): which is the best technetium-99m sestamibi modality?. *Surgery*, **2006**, 140, 856-63; discussion 863-5	3.6	62
129	Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. *Annals of Surgical Oncology*, **2015**, 22, 2295-301	3.1	61
128	Gastrointestinal tract malignancies and positron emission tomography: an overview. *Seminars in Nuclear Medicine*, **2006**, 36, 169-81	5.4	60
127	Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. *American Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 3, 85-96	2.2	60
126	Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose. *Molecular Imaging and Biology*, **2014**, 16, 322-9	3.8	59
125	Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) with PET in renal carcinoma. *Molecular Imaging and Biology*, **2009**, 11, 434-8	3.8	50
124	PET Tracers Beyond FDG in Prostate Cancer. *Seminars in Nuclear Medicine*, **2016**, 46, 507-521	5.4	48
123	Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy. *Annals of Surgical Oncology*, **2014**, 21, 93-9	3.1	46
122	Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. *Nuclear Medicine and Biology*, **2013**, 40, 670-5	2.1	45
121	Prompt-gamma compensation in Rb-82 myocardial perfusion 3D PET/CT. *Journal of Nuclear Cardiology*, **2010**, 17, 247-53	2.1	44
120	Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. *Journal of Nuclear Medicine*, **2016**, 57, 1357-63	8.9	39
119	Gallium and other agents in diseases of the lung. *Seminars in Nuclear Medicine*, **2002**, 32, 193-211	5.4	38
118	A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. *Journal of Vascular and Interventional Radiology*, **2014**, 25, 277-87	2.4	36
117	Comparative evaluation of transport mechanisms of trans-1-amino-3-[□□]fluorocyclobutanecarboxylic acid and L-[methyl-□□C]methionine in human glioma cell lines. *Brain Research*, **2013**, 1535, 24-37	3.7	35
116	[(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. *Nuclear Medicine and Biology*, **2015**, 42, 887-92	2.1	34
115	PET-CT vs contrast-enhanced CT: what is the role for each after chemoradiation for advanced oropharyngeal cancer?. *Head and Neck*, **2006**, 28, 487-95	4.2	34

114	Imaging of Prostate Cancer Using Fluciclovine. *PET Clinics*, **2017**, 12, 145-157	2.2	33
113	ACR Appropriateness Criteria Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. *Journal of the American College of Radiology*, **2017**, 14, S245-S257	3.5	30
112	Impact of F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. *Journal of Nuclear Medicine*, **2017**, 58, 412-418	8.9	30
111	F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. *Lancet, The*, **2021**, 397, 1895-1904	40	29
110	Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. *Journal of Nuclear Medicine*, **2016**, 57, 61S-66S	8.9	29
109	Prospective evaluation of fluciclovine (F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. *European Journal of Radiology*, **2018**, 102, 1-8	4.7	28
108	Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. *Molecular Imaging and Biology*, **2014**, 16, 756-64	3.8	28
107	ACR Appropriateness Criteria Pretreatment Staging of Muscle-Invasive Bladder Cancer. *Journal of the American College of Radiology*, **2018**, 15, S150-S159	3.5	28
106	Absent coronary artery calcium excludes inducible myocardial ischemia on computed tomography/positron emission tomography. *International Journal of Cardiology*, **2011**, 147, 424-7	3.2	27
105	[F]Fluciclovine PET discrimination between high- and low-grade gliomas. *EJNMMI Research*, **2018**, 8, 67	3.6	26
104	PET Molecular Imaging-Directed Biopsy: A Review. *American Journal of Roentgenology*, **2017**, 209, 255-269	3.4	25
103	Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma. *Journal of Vascular and Interventional Radiology*, **2014**, 25, 288-95	2.4	25
102	[F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 579-591	8.8	25
101	Imaging of Prostate Cancer Using Fluciclovine. *Urologic Clinics of North America*, **2018**, 45, 489-502	2.9	25
100	Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions. *Molecular Imaging and Biology*, **2013**, 15, 633-43	3.8	24
99	Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?. *Clinical Nuclear Medicine*, **2015**, 40, e196-200	1.7	22
98	Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 206-13	4	22
97	Automatic 3D Segmentation of Ultrasound Images Using Atlas Registration and Statistical Texture Prior. *Proceedings of SPIE*, **2011**, 7964,	1.7	22

96	90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. *Clinical Nuclear Medicine*, **2016**, 41, 21-7	1.7	22
95	(90)Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery. *Radiographics*, **2015**, 35, 1602-18	5.4	20
94	Bayesian penalised likelihood reconstruction (Q.Clear) of F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation. *British Journal of Radiology*, **2018**, 91, 20170727	3.4	20
93	Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology*, **2012**, 23, 943-8	2.4	20
92	The use of the diagnostic radionuclide ascites scan to facilitate treatment decisions for hepatic hydrothorax. *Clinical Nuclear Medicine*, **1998**, 23, 16-8	1.7	19
91	ACR Appropriateness Criteria Post-treatment Follow-up Prostate Cancer. *Journal of the American College of Radiology*, **2018**, 15, S132-S149	3.5	19
90	Automatic segmentation of the prostate on CT images using deep learning and multi-atlas fusion. *Proceedings of SPIE*, **2017**, 10133,	1.7	18
89	Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. *American Journal of Roentgenology*, **2019**, 213, 851-858	5.4	18
88	A Molecular Image-directed, 3D Ultrasound-guided Biopsy System for the Prostate. *Proceedings of SPIE*, **2012**, 2012,	1.7	18
87	Involving users in the implementation of an imaging order entry system. *Journal of the American Medical Informatics Association: JAMIA*, **2003**, 10, 315-21	8.6	17
86	The malady of incomplete, inadequate, and inaccurate radiology requisition histories: a computerized treatment. *American Journal of Roentgenology*, **1996**, 167, 855-9	5.4	16
85	Breast angiosarcoma: FDG PET findings. *Clinical Nuclear Medicine*, **2009**, 34, 443-5	1.7	15
84	PET Tracer F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models. *Theranostics*, **2017**, 7, 2048-2064	12.1	14
83	A combined learning algorithm for prostate segmentation on 3D CT images. *Medical Physics*, **2017**, 44, 5768-5781	4.4	14
82	Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design. *Clinical Nuclear Medicine*, **2009**, 34, 279-84	1.7	14
81	Xanthogranulomatous pyelonephritis characterized on PET/CT. *Clinical Nuclear Medicine*, **2005**, 30, 728-9	1.7	14
80	Esophageal scarring causing false-positive uptake on I-131 whole-body imaging. *Clinical Nuclear Medicine*, **1998**, 23, 334	1.7	14
79	Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma. *Molecular Imaging and Biology*, **2011**, 13, 1272-7	3.8	13

78	CT with histopathologic correlation of FDG uptake in a patient with pulmonary granuloma and pleural plaque caused by remote talc pleurodesis. *American Journal of Roentgenology*, **2004**, 182, 92-4	5.4	13
77	Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?. *American Journal of Roentgenology*, **2016**, 207, 635-40	5.4	12
76	PET-directed, 3D Ultrasound-guided prostate biopsy **2013**, 29, 12-15		12
75	Magnetic resonance cholangiography. *Abdominal Imaging*, **1995**, 20, 353-6		11
74	[F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. *Journal of Urology*, **2020**, 204, 734-740	2.5	11
73	Role of novel imaging in the management of prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 611-618	2.8	10
72	Reproducibility and reliability of anti-3-[□F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis. *Molecular Imaging and Biology*, **2015**, 17, 277-83	3.8	10
71	Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. *Nuclear Medicine and Biology*, **2018**, 59, 22-28	2.1	10
70	18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?. *European Journal of Radiology*, **2015**, 84, 1171-6	4.7	10
69	Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin□s lymphoma. *Clinical Nuclear Medicine*, **2007**, 32, 569-71	1.7	10
68	Amino Acid Metabolism as a Target for Breast Cancer Imaging. *PET Clinics*, **2018**, 13, 437-444	2.2	10
67	A semiautomatic segmentation method for prostate in CT images using local texture classification and statistical shape modeling. *Medical Physics*, **2018**, 45, 2527-2541	4.4	9
66	Fasting Enhances the Contrast of Bone Metastatic Lesions in F-Fluciclovine-PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	9
65	Unusual presentations of metastatic prostate carcinoma as detected by anti-3 F-18 FACBC PET/CT. *Clinical Nuclear Medicine*, **2011**, 36, 800-2	1.7	9
64	A PET/CT Directed, 3D Ultrasound-Guided Biopsy System for Prostate Cancer. *Lecture Notes in Computer Science*, **2011**, 6363, 100-108	0.9	9
63	Molecular imaging and fusion targeted biopsy of the prostate. *Clinical and Translational Imaging*, **2017**, 5, 29-43	2	8
62	F-Fluciclovine Parameters on Targeted Prostate Biopsy Associated with True Positivity in Recurrent Prostate Cancer. *Journal of Nuclear Medicine*, **2019**, 60, 1531-1536	8.9	8
61	Investigation of emission-transmission misalignment artifacts on rubidium-82 cardiac PET with adenosine pharmacologic stress. *Molecular Imaging and Biology*, **2008**, 10, 201-8	3.8	8

60	Molecular imaging in breast cancer. *Radiologic Clinics of North America*, **2004**, 42, 885-908, vi-vii	2.3	8
59	Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization: Outcomes at a Large Tertiary Care Center. *Clinical Nuclear Medicine*, **2020**, 45, 100-104	1.7	8
58	Combining Population and Patient-Specific Characteristics for Prostate Segmentation on 3D CT Images. *Proceedings of SPIE*, **2016**, 9784,	1.7	7
57	Radiation field design and patterns of locoregional recurrence following definitive radiotherapy for breast cancer. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 309-14	4	7
56	A rare presentation of myocardial plasmacytoma assessed by FDG PET/CT. *Clinical Nuclear Medicine*, **2014**, 39, 643-5	1.7	6
55	Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. *Journal of Urology*, **2019**, 202, 413-421	2.5	6
54	PET Imaging for Prostate Cancer. *Radiologic Clinics of North America*, **2021**, 59, 801-811	2.3	6
53	Central line injection artifact simulating paratracheal adenopathy on FDG PET imaging. *Clinical Nuclear Medicine*, **2004**, 29, 735-7	1.7	5
52	Jejunal diverticular hemorrhage localized by red blood cell scintigraphy. *Clinical Nuclear Medicine*, **2001**, 26, 936-7	1.7	5
51	F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. *Practical Radiation Oncology*, **2020**, 10, 354-362	2.8	5
50	F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 997-1006	6.2	5
49	The nuclear medicine therapy care coordination service: a model for radiologist-driven patient-centered care. *Academic Radiology*, **2015**, 22, 771-8	4.3	4
48	[F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis. *EJNMMI Research*, **2020**, 10, 148	3.6	4
47	Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?. *European Journal of Radiology*, **2016**, 85, 319-23	4.7	3
46	Current Clinical Practice Patterns of Self-Identified Nuclear Medicine Specialists. *American Journal of Roentgenology*, **2018**, 211, 978-985	5.4	3
45	ACR Appropriateness Criteria Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia. *Journal of the American College of Radiology*, **2019**, 16, S378-S383	3.5	3
44	Radionuclide Therapies in Molecular Imaging and Precision Medicine. *PET Clinics*, **2017**, 12, 93-103	2.2	3
43	Accuracy Evaluation of a 3D Ultrasound-guided Biopsy System. *Proceedings of SPIE*, **2013**, 8671,	1.7	3

42	Posterior bladder layering of excreted 18F-FDG on PET/CT. *Nuclear Medicine Communications*, **2010**, 31, 859-63	1.6	3
41	A semiautomatic algorithm for three-dimensional segmentation of the prostate on CT images using shape and local texture characteristics. *Proceedings of SPIE*, **2018**, 10576,	1.7	3
40	Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know. *Seminars in Interventional Radiology*, **2020**, 37, 543-554	1.6	3
39	Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer. *Nuclear Medicine Communications*, **2021**, 42, 402-409	1.6	3
38	Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization. *CardioVascular and Interventional Radiology*, **2021**, 44, 1194-1203	2.7	3
37	Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT. *Journal of Vascular and Interventional Radiology*, **2021**, 32, 752-760	2.4	3
36	Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?. *CardioVascular and Interventional Radiology*, **2021**, 44, 254-260	2.7	3
35	Role of F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: Expert Panel Narrative Review. *American Journal of Roentgenology*, **2021**, 216, 851-859	5.4	3
34	Molecular imaging of advanced prostate cancer. *Current Problems in Cancer*, **2015**, 39, 29-32	2.3	2
33	Biodistribution and human dosimetry of enantiomer-1 of the synthetic leucine analog anti-1-amino-2-fluorocyclopentyl-1-carboxylic acid. *Nuclear Medicine and Biology*, **2011**, 38, 1035-41	2.1	2
32	In OctreoScan SPECT-MRI fusion for the detection of a pancreatic insulinoma. *Clinical Nuclear Medicine*, **2012**, 37, e53-6	1.7	2
31	Choroidal melanoma with hematogenous spread to the liver: F-18 FDG PET/CT findings. *Clinical Nuclear Medicine*, **2006**, 31, 347-8	1.7	2
30	The integrative hospital explored via acupuncture. *Journal of Alternative and Complementary Medicine*, **1996**, 2, 503-14	2.4	2
29	Deep learning-based three-dimensional segmentation of the prostate on computed tomography images. *Journal of Medical Imaging*, **2019**, 6, 025003	2.6	2
28	Focal Hepatic Hot Spot From Superior Vena Cava Occlusion Visualized on Ventilation/Perfusion Scintigraphy With Contrast-Enhanced CT Correlate. *Clinical Nuclear Medicine*, **2016**, 41, 401-2	1.7	2
27	Re: "Cost-Savings Analysis of Renal Scintigraphy, Stratified by Renal Function Thresholds: Mercaptoacetyltriglycine Versus Diethylene Triamine Penta-Acetic Acid". *Journal of the American College of Radiology*, **2017**, 14, 146	3.5	1
26	Random Walk Based Segmentation for the Prostate on 3D Transrectal Ultrasound Images. *Proceedings of SPIE*, **2016**, 9786,	1.7	1
25	Imaging quality of F-18-FDG PET/CT in the inpatient versus outpatient setting. *Annals of Nuclear Medicine*, **2013**, 27, 508-14	2.5	1

24	A semiautomatic approach for prostate segmentation in MR images using local texture classification and statistical shape modeling. *Proceedings of SPIE*, **2019**, 10951,	1.7	1
23	Multisite experience of fluciclovine (18F) PET/CT imaging in biochemically recurrent prostate cancer: Impact of clinical factors and intersite variation.. *Journal of Clinical Oncology*, **2017**, 35, 163-163	2.2	1
22	ACR Appropriateness Criteria Recurrent Lower Urinary Tract Infections in Females. *Journal of the American College of Radiology*, **2020**, 17, S487-S496	3.5	1
21	Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT. *Clinical Nuclear Medicine*, **2021**, 46, e240-e241	1.7	1
20	Characterizing and Mitigating Bladder Radioactivity on F-Fluciclovine PET/CT. *Journal of Nuclear Medicine Technology*, **2020**, 48, 24-29	1.1	1
19	Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on F-Fluciclovine PET/CT Guidance. *Journal of Nuclear Medicine*, **2021**, 62, 1089-1096	8.9	1
18	Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma. *CardioVascular and Interventional Radiology*, **2021**, 44, 1937-1944	2.7	1
17	Clinical utility of F-Fluciclovine PET/CT in recurrent prostate cancer with very low (0.3 ng/mL) prostate-specific antigen levels. *American Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 11, 406-414	2.2	1
16	Incidental Detection of Lung Adenocarcinoma Presenting as an Anterior Mediastinal Mass on 18F-Fluciclovine PET/CT in a Patient With Primary Prostate Cancer. *Clinical Nuclear Medicine*, **2020**, 45, e525-e527	1.7	0
15	Exploratory study of F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. *American Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 11, 218-229	2.2	0
14	Malignant supraclavicular lymph node visualization during Tc-99m HDP bone imaging. *Clinical Nuclear Medicine*, **2000**, 25, 376-7	1.7	0
13	Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis. *Nuclear Medicine Communications*, **2021**, 42, 892-898	1.6	0
12	Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond. *World Journal of Gastrointestinal Oncology*, **2021**, 13, 440-452	3.4	0
11	ACR Appropriateness Criteria Staging and Surveillance of Testicular Cancer: 2021 Update.. *Journal of the American College of Radiology*, **2022**, 19, S194-S207	3.5	0
10	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2022**, 1-17	7.1	0
9	Metastatic Breast Lesion to the Falx Detected with PET-CT. *Nuclear Medicine and Molecular Imaging*, **2012**, 46, 147-9	1.9	
8	Heme products post-radiofrequency ablation obscure tumor recurrence on MR but not on PET-CT. *Nuclear Medicine and Molecular Imaging*, **2012**, 46, 152-4	1.9	
7	Four-dimensional (4D) motion detection to correct respiratory effects in treatment response assessment using molecular imaging biomarkers. *TCRT Express*, **2014**, 13, 571-82		

6	One possible future. *Journal of Alternative and Complementary Medicine*, **1998**, 4, 255-6	2.4
5	Radiologic Assessment of Esophageal Cancer **2020**, 139-157	
4	Ring Sclerosis in Prostate Cancer: Circle of Malignancy or Benignity?. *Clinical Nuclear Medicine*, **2021**, 46, e286-e289	1.7
3	Artifactual perfusion defect from a hypertrophic first costosternal articulation. *Clinical Nuclear Medicine*, **1997**, 22, 642	1.7
2	Radiologic Assessment of Esophageal Cancer **2015**, 105-121	
1	PERCIST criteria to predict survival at 3 months following intra-arterial resin-based yttrium-90 (Y-90) radioembolization therapy of unresectable intrahepatic cholangiocarcinoma refractory to standard chemotherapy: A proof of concept study.. *Journal of Clinical Oncology*, **2013**, 31, e15141-e15141	2.2